Nucana looked to harness the anti-cancer potential of Cordycepin and better equip it to navigate these considerable roadblocks, through what it calls ProTide technology. This is designed specifically to address the shortcomings of nucleoside analogues. It works by attaching small chemical groups to the compound that make it more resistant to breakdown in the bloodstream, and also enables them to enter cancer cells without the help of nucleoside transporters. The upshot is far greater levels of anti-cancer metabolites are generated and activated inside tumor cells.